The study is being conducted to demonstrate that ProQuad™ may be administered concomitantly with a fourth dose of Prevnar™ and a third dose of IPOL™ without impairing the safety or immunogenicity of vaccines for measles, mumps, rubella, varicella, 7 serotypes of S. pneumoniae or 3 serotypes of poliovirus.

Ages Eligible for Study:  12 Months   -   15 Months,  Genders Eligible for Study:  Both

Accepts Healthy Volunteers

Criteria

Inclusion Criteria:

• In good health
• 12 to 15 months of age
• Negative clinical history to measles, mumps, rubella, varicella and/or zoster
• Received only the 2-dose primary series of IPOL™ with the second dose at least 2 months prior to the receipt of any study vaccines and received the 3-dose primary series of Prevnar™ with at least 2 months prior to the receipt of any of the study vaccines
• Signed consent

Exclusion Criteria:

• Previous administration of any measles, mumps, rubella, or varicella vaccine either alone or in any combination
• Received OPV or Pediarix™
• Any condition resulting in depressed immunity
• Any allergy to any vaccine component as stated in the package circulars
• Exposure to measles, mumps, rubella, varicella, or zoster within 4 weeks prior to the study vaccination
• History of seizure disorder
• Receipt of an inactivated vaccine within 14 days prior to enrollment or live vaccine within 30 days
• Recent febrile illness